Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer

Inclusion criteria

• . Be able to understand and be willing to sign the written informed consent for the trial. A signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure.
• . Be ≥ 18 years of age on day of signing informed consent.
• . Histologically confirmed cancer of the pancreas (KRAS mutated) with metastases and progression on at least ≥ 2 prior treatment regimens for their disease.
• . Known mutation status of KRAS and BRAF kinases. For those patients in which this has not previously been determined, the patient must have an archival tumor specimen (primary or metastatic site) available to submit to confirm KRAS and BRAF status.
• . Have a performance status of 0 or 1 on the ECOG performance scale.
• . Demonstrate adequate organ function
• . Female participants of childbearing potential must have a negative serum pregnancy test performed within 24 hours prior to receiving first dose of trial medication. Post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test.
• . A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

Exclusion criteria